



[12] Patent

[11] Patent No.: GC 0000202	Number of the Decision to Grant the Patent: 5/994
[45] Date of Publishing the Grant of the Patent: 29/03/2006 5/2006	Date of the Decision to Grant the Patent: 02/07/2005
[21] Application No.: GCC/P/2000/893 [22] Filing Date: 06/09/2000 [30] Priority: [31] Priority No. [32] Priority date [33] State 9921147.6 07/09/1999 GB [72] Inventor: Wettendroff Martine Anne [73] Owner: SmithKline Beecham Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart, Belgium [74] Agent: Hassan Al-Mulla	[51] Int.Cl. ⁷ : A61K 39/295; A61P 31/20 [56] Cited Documents: - WO 99 45957 A (SMITHKLINE BEECHAM BIOLOG) 16 September 1999 - WO 95 17209 A (SMITHKLINE BEECHAM BIOLOG) 29 June 1995 - WO 95 17210 A (SMITHKLINE BEECHAM BIOLOG) 29 June 1995 - WO 94 21292 A (SMITHKLINE BEECHAM BIOLOG) 29 September 1999 - WO 93 19780 A (SMITHKLINE BEECHAM BIOLOG) 14 October 1993 - WO 92 11291 A (SMITHKLINE BEECHAM BIOLOG) 09 July 1992 - TINDLE et al., 1994

[54] COMBINED VACCINE COMPOSITION COMPRISING A HEPATITIS B VIRAL (HBV) ANTIGEN AND A HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN

[57] Abstract: Novel combined vaccine compositions are provided, comprising a hepatitis B viral antigen and an HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a herpes simplex viral antigen, a VZV antigen, an HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.

No. of claims: 20

No. of figures: 10